Last reviewed · How we verify

Metoclopramide and Ondanteron — Competitive Intelligence Brief

Metoclopramide and Ondanteron (Metoclopramide and Ondanteron) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiemetic/Prokinetic combination. Area: Gastroenterology.

phase 3 Antiemetic/Prokinetic combination Dopamine receptors (D2) and 5-HT3 serotonin receptors Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Metoclopramide and Ondanteron (Metoclopramide and Ondanteron) — Shahid Beheshti University of Medical Sciences. This combination blocks dopamine receptors (metoclopramide) to enhance gastric motility and blocks serotonin 5-HT3 receptors (ondansetron) to prevent nausea and vomiting.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Metoclopramide and Ondanteron TARGET Metoclopramide and Ondanteron Shahid Beheshti University of Medical Sciences phase 3 Antiemetic/Prokinetic combination Dopamine receptors (D2) and 5-HT3 serotonin receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiemetic/Prokinetic combination class)

  1. Shahid Beheshti University of Medical Sciences · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Metoclopramide and Ondanteron — Competitive Intelligence Brief. https://druglandscape.com/ci/metoclopramide-and-ondanteron. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: